Literature DB >> 19397539

Glucose infusions into peripheral veins in the management of neonatal hypoglycemia--20% instead of 15%?

T Vanhatalo1, O Tammela.   

Abstract

AIM: To establish whether peripheral intravenous 20% glucose solutions would cause less local irritation, fewer cannulation changes and less weight gain than 15% glucose in newborn infants.
METHODS: A total of 121 newborn infants with hypoglycemia were randomized to receive either 20% (group 20%, 60 infants) or 15% (group 15%, 61 infants) glucose infusions, which were initiated at 8 mg/kg/min rates and tapered according to the blood glucose levels. When the cannulation site had to be changed, signs of phlebitis at the previous cannulation site were scored (0-3). Number of cannulation site changes, durations of infusions and the infants' daily weights were recorded.
RESULTS: The median durations of infusions in groups 20 and 15% were 4 (range 2-7) days versus 4 (range 2-8) days and the median number of cannulation site changes were 1 (range 0-6) versus 1 (range 0-5), respectively. Thirty-six infants in group 20% and 37 in group 15% developed some phlebitis, median severity scores being 1 (range 0-7) versus 15% 1 (range 0-8). The weights during the treatment were also similar.
CONCLUSION: 20% and 15% glucose solutions can be infused equally safely into peripheral veins in neonates.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19397539     DOI: 10.1111/j.1651-2227.2009.01237.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  2 in total

Review 1.  The screening and management of newborns at risk for low blood glucose.

Authors:  Michael R Narvey; Seth D Marks
Journal:  Paediatr Child Health       Date:  2019-12-09       Impact factor: 2.253

2.  A novel algorithm in the management of hypoglycemia in newborns.

Authors:  Swapna Naveen; Chikati Rosy; Hemasree Kandraju; Deepak Sharma; Tejopratap Oleti; Srinivas Murki
Journal:  Int J Pediatr       Date:  2014-11-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.